This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.
ASCO 2015 Breast Cancer Symposium
Caveolin-1 (CAV1) appears to play an oncogenic role in breast cancer by fostering molecular hubs for signaling, and should be considered a potential target for therapeutic investigation, in particular in triple-negative disease.
Multigene panels can detect significant pathogenic mutations in a proportion of breast cancer patients who have tested negative for BRCA1/2 gene mutations, according to a new study.
High expression of the known tumor promotor TOX3 gene leads to poorer prognosis in breast cancer patients with luminal B disease, according to a new study.
Neratinib Improves Invasive Disease-Free Survival in Centrally Confirmed HER2-Positive Breast Cancer
Neratinib significantly improves invasive disease-free survival (iDFS) in trastuzumab (Herceptin)-treated, early-stage, human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients, with an enhanced treatment effect observed in women with centrally confirmed HER2+ tumors.
More accurate identification of molecular subtyping for breast cancer may be able to identify patients with chemosensitivity to specific therapies, according to a new study.
Aromatase inhibitors can reduce risk of contralateral breast cancer in women who have a BRCA mutation, according to a new study.
Tumors from elderly breast cancer patients carry unique features compared to their younger counterparts, according to a new study.
Ahead of the 2015 ASCO Breast Cancer Symposium, Saima Noor Hassan, MD, PhD, discusses her upcoming presentation on PARP inhibitors in breast cancer.